Navigation Links
ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
Date:7/14/2009

HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax(TM) delivery platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company will fast-track DPX-0907 into Phase 1 clinical trials.

"Advanced-stage breast, ovarian and prostate cancers remain devastating and challenging diseases that urgently need treatment options, and we are excited to use Immunotope's antigens in our platform" said Dr. Randal Chase, president CEO of IVT. "This licensing agreement significantly advances our cancer immunotherapy capabilities and represents our continued commitment to developing our DepoVax(TM) technology within a robust clinical trial program."

"This agreement combines our antigen discovery expertise with IVT's product development capabilities and we are pleased to have our antigens become part of such an innovative vaccine candidate," said Ramila Philip, president and CSO of Immunotope Inc.

Under the license agreement, IVT has agreed to an up-front payment, as well as future milestone payments and royalties to Immunotope for use of the antigens. This licensing agreement replaces the acquisition of Immunotope agreement.

DPX-0907 is a novel vaccine because of its potential to create a depot at the injection site and cause a strong, rapid, long-lasting immune response that specifically targets cancer cells.

ImmunoVaccine Technologies is strengthening its innovative vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary DepoVax(TM) technology for two liv
'/>"/>

SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
2. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
3. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
4. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
5. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
8. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
9. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
10. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
11. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering ... the Orange County, Texas area from future storm surge flooding, such as occurred in ... potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... ... Sherley says the company is making good progress in evaluating the full range ... adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials can ... of liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external ... What immediately catches the eye about Xsample 530 is its removable magazine, which is easily ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... NEW YORK, Sept. 8 Reportlinker.com announces that a new ... Nanoporous Materials , , ... , This report analyzes the Global Market for Nanoporous ... Nanoporous (Microporous) Materials by the following product segments: Zeolites, Activated Carbon, ...
... NEW YORK, Sept. 8 Reportlinker.com announces that a new ... , Small Molecule Kinase Inhibitors ... , , This report ... Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, ...
... , Dan Ross to Lead Business Development Team ... a value strategy consultancy that provides pricing and reimbursement services to ... hired Dan Ross to open its new San Diego office. , ... with healthcare companies in both investment banking and strategic consulting capacities. ...
Cached Biology Technology:Reportlinker Adds Nanoporous Materials Report 2Reportlinker Adds Nanoporous Materials Report 3Reportlinker Adds Nanoporous Materials Report 4Reportlinker Adds Nanoporous Materials Report 5Reportlinker Adds Nanoporous Materials Report 6Reportlinker Adds Small Molecule Kinase Inhibitors Report 2Reportlinker Adds Small Molecule Kinase Inhibitors Report 3Reportlinker Adds Small Molecule Kinase Inhibitors Report 4Reportlinker Adds Small Molecule Kinase Inhibitors Report 5Reportlinker Adds Small Molecule Kinase Inhibitors Report 6Reportlinker Adds Small Molecule Kinase Inhibitors Report 7Reportlinker Adds Small Molecule Kinase Inhibitors Report 8Reportlinker Adds Small Molecule Kinase Inhibitors Report 9Reportlinker Adds Small Molecule Kinase Inhibitors Report 10PriceSpective Continues Global Expansion With New San Diego Office 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... 19, 2013) The AGA Research Foundation is honored ... Augustyn Award in Digestive Cancer, which will support Andrew ... at the University of Pennsylvania, Philadelphia, as he furthers ... development, regeneration and cancer progression. "The AGA Research ...
... Research presented at Digestive Disease Week (DDW) explores ... lifestyle. Individuals suffering from Crohn,s disease are ... quality of life. These symptoms can remain even when ... study found for the first time that vitamin D ...
... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ...
Cached Biology News:AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: